GlassScriptPhysician profile
Mary K Martin
NPI 1477863082
$11,416.89
in general payments reported to CMS, 2019-2025
23 companies · $3,119 in 2025
The $3,119 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,684 · 2022: $2,183 · 2023: $2,312 · 2024: $2,119 · 2025: $3,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,522 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,522.09 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,042.05 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,731.08 | 2021-2025 | |
| Alkermes, INC. | $1,248.86 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $1,183.71 | 2021-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $793.27 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $790.91 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $616.95 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $604.56 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Corium, LLC | $427.00 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $255.01 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Horizon Therapeutics Plc | $250.19 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $235.85 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $231.21 | 2021-2023 | Aplenzin, Wellbutrin |
| Sunovion Pharmaceuticals INC. | $200.37 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $199.25 | 2023-2024 | Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $162.08 | 2022-2024 | Jornay Pm |
| Almatica Pharma LLC | $124.37 | 2023-2025 | Loreev Xr |
| Acadia Pharmaceuticals INC | $124.09 | 2021-2025 | Nuplazid |
| Collegium Pharmaceutical, INC. | $116.78 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $24.77 | 2024 | Fanapt, Hetlioz |
| Tris Pharma INC | $19.85 | 2022 | |
| Alfasigma USA, INC. | $19.37 | 2021 | |
| Abbott Laboratories | $15.31 | 2024 | Jot Dx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.